Research programme: orphan disease therapeutics - Aevi Genomic Medicine/The Childrens Hospital of Philadelphia

Drug Profile

Research programme: orphan disease therapeutics - Aevi Genomic Medicine/The Childrens Hospital of Philadelphia

Alternative Names: AEVI-005; MDGN-204; MDGN-206

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medgenics; The Childrens Hospital of Philadelphia
  • Developer Aevi Genomic Medicine; Kyowa Hakko Kirin; The Childrens Hospital of Philadelphia
  • Class Gene therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Metabolic disorders
  • Research Autoimmune disorders

Most Recent Events

  • 07 Mar 2018 Aevi Genomic Medicine and Kyowa Hakko Kirin agree to co-develop monoclonal antibody for ultra-orphan paediatric indication
  • 07 Mar 2018 Early research in Autoimmune disorders in Japan and USA (Parenteral)
  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top